Alliance will provide a new therapy for rare CNS disease 

Map of Europe

Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe. 

The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). 

Minoryx has granted Neuraxpharm exclusive European rights to leriglitazone, a novel, brain penetrant and selective PPAR gamma agonist. Minoryx retains full rights in the US and the rest of world, excluding already partnered China. 

As part of the agreement, Neuraxpharm has agreed to pay Minoryx an upfront payment in addition to milestone payments and development funding totalling up to 258 million. 

Leriglitazone will be the first approved treatment for adult male patients with X-ALD if it is approved by the EMA. Minoryx and Neuraxpharm will continue the development of leriglitazone for additional X-ALD patient populations and other orphan indications.


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free